EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Effectiveness of a Novel Caffeine Nano-Cream for Cellulite Reduction: A Randomised Double-Blind Trial

Thellie Ponto iD, Christofori M R R Nastiti iD, Giuseppe Luna iD, Vânia R Leite-Silva iD, Brioni R Moore iD, Anthony Wright iD, Heather A E Benson iD

Pharmaceutics · 24.01.2026 · 18 (2) · 151

DOI: 10.3390/pharmaceutics18020151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 24.01.2026. Verfasst von Thellie Ponto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Curtin Medical School, Curtin University, Perth, WA 6102, Australia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Government, Curtin University, RTP scholarship from the Australian Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Caffeine (CAF), whether extracted from plants or synthesised as a chemical compound, is considered the safest among other xanthine alkaloids. Novel nano-cream formulations have been successfully developed and evaluated to increase the potential of caffeine as a skin cosmeceutical, targeting the minimisation of cellulite appearance.

Methods

Nano-cream formulations were prepared through a process of hot-temperature emulsification, in a variety of homogeniser combinations.

Results

When chemical penetration enhancers (CPEs) (lanolin, transcutol, and propylene glycol), either alone or in combination, were incorporated into the nano-cream formulations, the permeation of CAF through skin increased. All nano-cream formulations achieved sustained delivery of CAF into and through the skin over 8 h (IVPT). Quantification of CAF from skin tissues was achieved using high-performance liquid chromatography (HPLC). The nano-cream formulation containing lanolin (LAN) showed the highest CAF permeation (8.829 ± 1.472 µg/cm2/h) through the skin compared to CAF in an aqueous solution (2.533 ± 0.480 µg/cm2/h) and a commercial CAF cellulite product with the same CAF concentration (2.827 ± 0.555 µg/cm2/h). Therefore, 2% CAF nano-cream formulation containing LAN was chosen for clinical testing. A double-blind, randomised, placebo-controlled paired trial was conducted, in which each volunteer applied active and placebo creams to the upper thighs twice daily for 12 weeks. The effect of the cream on skin appearance was monitored over 12 weeks. The primary outcome measures were reduced cellulite scores from 3.96 (95% CI: 3.16–4.76) to 2.50 (95% CI: 1.70–3.30) (active) compared with placebo from 3.88 (95% CI: 3.08–4.67) to 2.83 (95% CI: 2.03–3.63). The effect sizes (E.S.) indicated a moderate effect for the active CAF nano-cream formulation (E.S. = 0.475), while the placebo (E.S. = 0.286) had a small effect.

Conclusion

We concluded that our optimised 2% CAF nano-cream formulation containing LAN offered an effective formulation strategy for enhancing skin penetration in the IVPT study. The LAN nano-cream formulation demonstrated efficacy and tolerability, both objectively and subjectively, in a human clinical trial.

Schlagwörter

Stichwörter der Autor:innen

caffeinecellulitechemical penetration enhancersclinical trialcosmeceuticalnano-cream formulationsskin targetingtopical delivery

Autor:innen und Institutionen

  • Curtin Medical School, Curtin University, Perth, WA 6102, Australia.
  • Division of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Sanata Dharma University, Yogyakarta 55282, Indonesia.
  • Departamento de Ciências Farmacêuticas, Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Universidade Federal de São Paulo, Rua São Nicolau, 210, Diadema 09913-030, Brazil.
  • Curtin Medical Research Institute, Curtin University, Perth, WA 6102, Australia.
  • School of Allied Health, Curtin University, Perth, WA 6102, Australia.

ORCID-Profile: Thellie Ponto, Christofori M R R Nastiti, Giuseppe Luna, Vânia R Leite-Silva, Brioni R Moore, Anthony Wright, Heather A E Benson

Förderung

  • Australian Government
  • Curtin University
  • RTP scholarship from the Australian Government

Zitieren

APA

Ponto, T., Nastiti, C. M. R. R., Luna, G., Leite-Silva, V. R., Moore, B. R., Wright, A., & Benson, H. A. E. (2026). Clinical Effectiveness of a Novel Caffeine Nano-Cream for Cellulite Reduction: A Randomised Double-Blind Trial. Pharmaceutics, 18(2), 151. https://doi.org/10.3390/pharmaceutics18020151

Vancouver

Ponto T, Nastiti CMRR, Luna G, Leite-Silva VR, Moore BR, Wright A, et al. Clinical Effectiveness of a Novel Caffeine Nano-Cream for Cellulite Reduction: A Randomised Double-Blind Trial. Pharmaceutics. 2026;18(2):151. doi:10.3390/pharmaceutics18020151

BibTeX
@article{Ponto2026,
  author = {Ponto, Thellie and Nastiti, Christofori M R R and Luna, Giuseppe and Leite-Silva, Vânia R and Moore, Brioni R and Wright, Anthony and Benson, Heather A E},
  title = {Clinical Effectiveness of a Novel Caffeine Nano-Cream for Cellulite Reduction: A Randomised Double-Blind Trial},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {2},
  pages = {151},
  doi = {10.3390/pharmaceutics18020151}
}
Kostenlos starten →